Compugen Ltd.
Last updated September 27, 2026
Organization details
- Legal name
- Compugen Ltd.
- Ownership
- Public
- Status
- Active
- Headquarters country
- Israel
- Ticker symbol
- CGEN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001119774
Board of directors
-
Anat Cohen-Dayag · DirectorSince 2026
-
Eran Ophir · Director · President and CEOSince 2026
-
Eran Perry · DirectorSince 2026
-
Gilead Halevy · DirectorSince 2026
-
Mathias Hukkelhoven · DirectorSince 2026
-
Michele Holcomb · DirectorSince 2026
-
Sanford S. Zweifach · DirectorSince 2026
-
Savitzky Kinneret Livnat · DirectorSince 2026
Chief executives
Eran Ophir
· President and CEO
Since March 2026
Board connections
1 of this board's directors also sit on 1 other board.
- via Michele Holcomb
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $118,301
- 11 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 29, 2026 | Mahler Michelle Officer (Chief Medical Officer) | Grant or award | +13,500 | — | — |
| Jul 29, 2026 | Sanford S. Zweifach Director | Grant or award | +7,500 | — | — |
| Jul 29, 2026 | Gilead Halevy Director | Grant or award | +7,500 | — | — |
| Jul 29, 2026 | Mathias Hukkelhoven Director | Grant or award | +7,500 | — | — |
| Jul 29, 2026 | Savitzky Kinneret Livnat Director | Grant or award | +7,500 | — | — |
| Jul 29, 2026 | Kredo Russo Sharon Officer (SVP, Research & Discovery) | Grant or award | +18,000 | — | — |
| Jul 29, 2026 | Eran Perry Director | Grant or award | +7,500 | — | — |
| Jul 29, 2026 | David Silberman Officer (Chief Financial Officer) | Grant or award | +19,500 | — | — |
| Jul 29, 2026 | Levine Zurit Officer (SVP, Business Development) | Grant or award | +18,000 | — | — |
| Jul 9, 2026 | Levine Zurit Officer (SVP, Business Development) | Option exercise | +1,875 | $0.83 | $1,555 |
| Jul 9, 2026 | Levine Zurit Officer (SVP, Business Development) | Open-market sale | −1,875 | $2.50 | $4,688 |
| Apr 24, 2026 | Levine Zurit Officer (SVP, Business Development) | Option exercise | +2,000 | $1.15 | $2,300 |
| Apr 24, 2026 | Eran Ophir Director, Officer (President and CEO) | Option exercise | +5,000 | $0.83 | $4,150 |
| Apr 24, 2026 | Levine Zurit Officer (SVP, Business Development) | Open-market sale | −2,000 | $3.20 | $6,400 |
| Apr 24, 2026 | Eran Ophir Director, Officer (President and CEO) | Open-market sale | −5,000 | $3.20 | $16,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.